Market Overview

UPDATE: Goldman Sachs Initiates Genomic Health at Neutral on Limited Upside

Related GHDX
CMS Increases Final Pricing Determination for Oncotype DX Breast Cancer Test to Previously Established Rate of $3,416
A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month
Philips Equips Pathologists with New Digitalized Services (Zacks)

Goldman Sachs initiated coverage on Genomic Health (NASDAQ: GHDX) with a Neutral rating and a $36 price target.

Goldman Sachs commented, "Our thesis is based on (1) growth potential from new product cycles offset by (2) underappreciated market development costs and (3) mounting competition and an uncertain regulatory environment. How we are different: Our proprietary analysis of GHDX's new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street."

Genomic Health closed at $33.77 on Wednesday.

Latest Ratings for GHDX

Aug 2015Raymond JamesUpgradesUnderperformMarket Perform
Aug 2015Canaccord GenuityMaintainsHold
May 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (GHDX)

Get Benzinga's Newsletters